logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

ADC Therapeutics: Moving from a Development-Stage Firm to a Revenue-Generating Firm

ADC Therapeutics First Quarter Financial Results and Business Updates ADC Therapeutics SA ( ADCT ) is a commercial-stage biotechnology company that creates novel antibody-drug conjugates ( ADCs ) for the treatment of hematological malignancies and solid tumors.   Today, ADC Therapeutics...

Read More

May 7, 2021

0

Navidea Biopharmaceuticals: Why This Small Firm's Stock Skyrocketed

Navidea Biopharmaceuticals Stock Soared Navidea Biopharmaceuticals ( NAVB ) stock price jumped from $1.27 to $3.04 this morning. The reason for the stock's soaring, according to the firm’s press release, was that interim data from a trial have further corroborated...

Read More

May 22, 2020

0

Reata Pharmaceuticals: Good News from the FDA Regarding Omaveloxolone for Friedreich’s Ataxia

Reata Pharmaceuticals Good News Reata Pharmaceuticals ( RETA ) announced it received a communication from the Division of Neurology Products of the U.S. FDA stating, that after a preliminary review of briefing materials for an upcoming Type C meeting, a...

Read More

May 19, 2021

0

A Potential Merger Between AstraZeneca Plc and Gilead Sciences?

AstraZeneca Plc and Gilead Sciences Potential Merger News spread through the media announcing that AstraZeneca Plc ( AZN ) has approached Gilead Sciences ( GILD ) regarding a possible, potential merger. People familiar with the subject (we don’t know who...

Read More

June 8, 2020

0

Prilenia Therapeutics' Pridopidine Product for Huntington's and Lou Gehrig's Diseases Could be Promising

Prilenia Therapeutics Prilenia Therapeutics is a clinical-stage biotech company. The firm’s leader, Michael Hayden, MD, PhD., is a world-renowned scientist in Huntington's Disease ( HD ) research. Dr. Hayden was the President of Global R&D and Chief Scientific Officer at...

Read More

May 25, 2021

0

Can Excision BioTherapeutics Inc Cure HIV?!

Excision BioTherapeutics, Inc. IND Application for EBT-101 for HIV Accepted by the US FDA Excision BioTherapeutics, Inc. , which focuses on developing CRISPR-based therapies intended to cure viral infectious diseases, announced that the U.S. FDA has accepted the firm’s Investigational...

Read More

September 24, 2021

0

Celldex Therapeutics: The Beginning of the Firm's Resurrection

Celldex Therapeutics A few years ago Celldex Therapeutics ( CLDX ) was known for its superior pipeline products. The most promising product in the firm's pipeline was Celldex’s lead drug designed to treat the untreatable terrible brain cancer known as...

Read More

June 12, 2020

0

Don't Miss the Enanta Pharmaceuticals Virtual Conference on October 19th - October 21st

Don't Miss Enanta Pharmaceuticals Virtual Conference Enanta Pharmaceuticals ( ENTA ) - a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that new preclinical data for EDP-235 - its lead oral...

Read More

October 11, 2021

0

Akero Therapeutics' Product Efruxifermin Demonstrates Strong Positive Results in NASH Patients

Akero Therapeutics Efruxifermin Positive Results in NASH Akero Therapeutics ( AKRO ) results of a 16-week analysis of secondary and exploratory endpoints in Phase 2a BALANCED study of its product efruxifermin ( EFX ), formerly known as AKR-001, in patients with...

Read More

July 1, 2020

0

The U.S. FDA Approved Oyster Point Pharma Inc Product TYRVAYA™ to Treat Dry Eye Disease

Oyster Point Pharma, Inc.  The U.S. Food and Drug Administration ( FDA ) has approved the Oyster Point Pharma Inc ( OYST ) product TYRVAYA™ (varenicline solution) Nasal Spray 0.03 mg for the treatment of signs and symptoms of dry eye disease. TYRVAYA™...

Read More

October 18, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 95
  • 96
  • 97
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy